FT819-102: Clinical Translation of Off-the-Shelf TCR-less CD8αβ+ anti-CD19 CAR-T Cells for The Treatment of B cell-mediated Autoimmune Disorders
Wednesday, May 8, 2024 1 min read
Key Takeaway: The article discusses the clinical translation of FT819-102, an off-the-shelf TCR-less CD8αβ+ anti-CD19 CAR-T cell therapy aimed at treating B cell-mediated autoimmune disorders. It highlights the potential of this innovative therapy but lacks specific details regarding outcomes or current trial status.
Price reaction · baseline $3.73 (2024-05-08T15:31:00.000Z) · hit during market hours · 3 other FATE headline(s) in the window, move may be shared
day 0 close · peak
-0.8%
Market Sentiment Analysis
Full Press Release Details
• Privacy Overview
• Strictly Necessary Cookies
• 3rd Party Cookies
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognizing you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
For more information about the data we collect please visit our Privacy Policy .
Strictly Necessary Cookies is enabled at all times so that we can save your preferences for cookie settings.
This website uses Google Analytics to collect information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.